- Home
- WAVE vs RLMD Comparison
WAVE vs RLMD Comparison
Compare WAVE & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WAVE
- RLMD
- Stock Information
- Founded
- WAVE 2011
- RLMD 2004
- Country
- WAVE Israel
- RLMD United States
- Employees
- WAVE N/A
- RLMD N/A
- Industry
- WAVE Electric Utilities: Central
- RLMD Biotechnology: Pharmaceutical Preparations
- Sector
- WAVE Utilities
- RLMD Health Care
- Exchange
- WAVE Nasdaq
- RLMD Nasdaq
- Market Cap
- WAVE 27.0M
- RLMD 22.0M
- IPO Year
- WAVE 2021
- RLMD N/A
- Fundamental
- Price
- WAVE $7.10
- RLMD $0.63
- Analyst Decision
- WAVE Strong Buy
- RLMD Buy
- Analyst Count
- WAVE 1
- RLMD 3
- Target Price
- WAVE $15.00
- RLMD $5.00
- AVG Volume (30 Days)
- WAVE 21.2K
- RLMD 432.4K
- Earning Date
- WAVE 05-08-2025
- RLMD 08-06-2025
- Dividend Yield
- WAVE N/A
- RLMD N/A
- EPS Growth
- WAVE N/A
- RLMD N/A
- EPS
- WAVE N/A
- RLMD N/A
- Revenue
- WAVE $168,000.00
- RLMD N/A
- Revenue This Year
- WAVE $325.00
- RLMD N/A
- Revenue Next Year
- WAVE $85.71
- RLMD N/A
- P/E Ratio
- WAVE N/A
- RLMD N/A
- Revenue Growth
- WAVE N/A
- RLMD N/A
- 52 Week Low
- WAVE $2.39
- RLMD $0.24
- 52 Week High
- WAVE $17.63
- RLMD $4.47
- Technical
- Relative Strength Index (RSI)
- WAVE 65.20
- RLMD 51.09
- Support Level
- WAVE $4.41
- RLMD $0.59
- Resistance Level
- WAVE $6.36
- RLMD $0.67
- Average True Range (ATR)
- WAVE 0.46
- RLMD 0.07
- MACD
- WAVE 0.18
- RLMD -0.02
- Stochastic Oscillator
- WAVE 99.63
- RLMD 52.97
About WAVE Eco Wave Power Global AB (publ)
Eco Wave Power Global AB is a Sweden-based wave energy company engaged in the development of a smart and cost-efficient WEC, technology that converts ocean and sea waves into clean electricity. Its WEC technology employs units of point absorber floating devices, referred to as floaters, which are installed on existing marine structures such as piers, breakwaters, and jetties, or in locations in which such marine structures are required. Geographical presence in Israel, USA and Mexico.
About RLMD Relmada Therapeutics Inc.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.